Hanx Biopharmaceuticals repurchases 58,200 H-shares, lifts treasury stock to 2.03 million units

Bulletin Express07-14

Hanx Biopharmaceuticals (Wuhan) Co., Ltd. disclosed that it repurchased 58,200 H-shares on 14 July 2026 via on-exchange transactions, paying a total of HKD 1.68 million at prices ranging from HKD 28.50 to HKD 29.88 per share. The volume-weighted average consideration stood at HKD 28.95 per share.

Following the transaction, Hanx Biopharmaceuticals’ issued share capital (excluding treasury shares) decreased by 0.043% to 134.19 million shares, while treasury shares rose to 2.03 million. Total issued shares remained unchanged at 136.22 million.

The buyback was executed under the repurchase mandate approved on 24 June 2026, which permits the company to repurchase up to 13.47 million shares. Cumulative buybacks since the mandate now total 0.50 million shares, representing 0.37% of the issued share base at the mandate date.

All regulatory requirements of the Hong Kong Stock Exchange’s Main Board Rules were met, and proceeds for the repurchase have been fully settled. In line with listing regulations, Hanx Biopharmaceuticals is subject to a moratorium on issuing new shares or disposing of treasury shares until 13 August 2026.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1133118332?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-14 19:42","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1133118332","market":"us","top_or_hot":-1,"title":"Hanx Biopharmaceuticals repurchases 58,200 H-shares, lifts treasury stock to 2.03 million units","media":"Bulletin Express","content":"<p>Hanx Biopharmaceuticals (Wuhan) Co., Ltd. disclosed that it repurchased 58,200 H-shares on 14 July 2026 via on-exchange transactions, paying a total of HKD 1.68 million at prices ranging from HKD 28.50 to HKD 29.88 per share. The volume-weighted average consideration stood at HKD 28.95 per share.</p>\n<p>Following the transaction, Hanx Biopharmaceuticals’ issued share capital (excluding treasury shares) decreased by 0.043% to 134.19 million shares, while treasury shares rose to 2.03 million. Total issued shares remained unchanged at 136.22 million.</p>\n<p>The buyback was executed under the repurchase mandate approved on 24 June 2026, which permits the company to repurchase up to 13.47 million shares. Cumulative buybacks since the mandate now total 0.50 million shares, representing 0.37% of the issued share base at the mandate date.</p>\n<p>All regulatory requirements of the Hong Kong Stock Exchange’s Main Board Rules were met, and proceeds for the repurchase have been fully settled. In line with listing regulations, Hanx Biopharmaceuticals is subject to a moratorium on issuing new shares or disposing of treasury shares until 13 August 2026.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hanx Biopharmaceuticals repurchases 58,200 H-shares, lifts treasury stock to 2.03 million units</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHanx Biopharmaceuticals repurchases 58,200 H-shares, lifts treasury stock to 2.03 million units\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-07-14 19:42</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Hanx Biopharmaceuticals (Wuhan) Co., Ltd. disclosed that it repurchased 58,200 H-shares on 14 July 2026 via on-exchange transactions, paying a total of HKD 1.68 million at prices ranging from HKD 28.50 to HKD 29.88 per share. The volume-weighted average consideration stood at HKD 28.95 per share.</p>\n<p>Following the transaction, Hanx Biopharmaceuticals’ issued share capital (excluding treasury shares) decreased by 0.043% to 134.19 million shares, while treasury shares rose to 2.03 million. Total issued shares remained unchanged at 136.22 million.</p>\n<p>The buyback was executed under the repurchase mandate approved on 24 June 2026, which permits the company to repurchase up to 13.47 million shares. Cumulative buybacks since the mandate now total 0.50 million shares, representing 0.37% of the issued share base at the mandate date.</p>\n<p>All regulatory requirements of the Hong Kong Stock Exchange’s Main Board Rules were met, and proceeds for the repurchase have been fully settled. In line with listing regulations, Hanx Biopharmaceuticals is subject to a moratorium on issuing new shares or disposing of treasury shares until 13 August 2026.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03378","symbol_name":"翰思艾泰-B","start_time":0,"source_url":"","article_id":"1133118332","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1133118332","pubTimestamp":1784029326,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Hanx Biopharmaceuticals (Wuhan) Co., Ltd. disclosed that it repurchased 58,200 H-shares on 14 July 2026 via on-exchange transactions, paying a total of HKD 1.68 million at prices ranging from HKD...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"03378":"翰思艾泰-B"},"translate_title":"汉克斯生物制药回购58,200股H股，库存增至203万股","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03378":1},"content_text":"Hanx Biopharmaceuticals (Wuhan) Co., Ltd. disclosed that it repurchased 58,200 H-shares on 14 July 2026 via on-exchange transactions, paying a total of HKD 1.68 million at prices ranging from HKD 28.50 to HKD 29.88 per share. The volume-weighted average consideration stood at HKD 28.95 per share.\nFollowing the transaction, Hanx Biopharmaceuticals’ issued share capital (excluding treasury shares) decreased by 0.043% to 134.19 million shares, while treasury shares rose to 2.03 million. Total issued shares remained unchanged at 136.22 million.\nThe buyback was executed under the repurchase mandate approved on 24 June 2026, which permits the company to repurchase up to 13.47 million shares. Cumulative buybacks since the mandate now total 0.50 million shares, representing 0.37% of the issued share base at the mandate date.\nAll regulatory requirements of the Hong Kong Stock Exchange’s Main Board Rules were met, and proceeds for the repurchase have been fully settled. In line with listing regulations, Hanx Biopharmaceuticals is subject to a moratorium on issuing new shares or disposing of treasury shares until 13 August 2026.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1133118332","isCrawlerRequest":true}